S100A10 and neoplasm: Tumor number incidence and size was monitored in LPTENKO mice with hepatocyte-specific knock-down of S100A10 or S100A11 through in vivo MRI imaging every month, in order to investigate the effect of S100A10/S100A11 downregulation on hepatic carcinogenesis in a MASLD context.